Table 1.
Compound Structure | Compound Number | CVB3 | ADV7 | ||||
---|---|---|---|---|---|---|---|
EC50 a (μM) |
CC50 b (μM) |
SI c | EC50 (μM) |
CC50 (μM) |
SI | ||
W1 | - | 594.2 ± 49.1d | - | - | 1057.1 ± 93.5 | - | |
W2 | 100.7 ± 14.1 | 240.3 ± 22.0 | 2.4 | 50.8 ± 16.7 | >655.7 | >12.9 | |
W3 | - | 630.4 ± 39.4 | - | - | 920.8 ± 59.5 | - | |
W4 | 54.4 ± 11.1 | 221.6 ± 24.1 | 4.1 | - | 796.9 ± 45.7 | - | |
W5 | - | 33.5 ± 9.4 | - | - | 38.9 ± 18.8 | - | |
W6 | 88.4 ± 19.5 | 243.9 ± 30.4 | 2.8 | 66.0 ± 20.1 | 325.7 ± 21.8 | 4.9 | |
W7 | - | 349.5 ± 28.8 | - | - | 1029.8 ± 63.1 | - | |
W8 | 80.1 ± 15.0 | 354.4 ± 49.5 | 4.4 | - | 842.7 ± 37.1 | - | |
W9 | 24.6 ± 8.7 | 148.0 ± 11.6 | 6.0 | 27.1 ± 9.0 | 265.3 ± 28.1 | 9.8 | |
W10 | 36.7 ± 15.8 | 184.2 ± 26.3 | 5.0 | 51.1 ± 20.1 | 249.2 ± 23.2 | 4.9 | |
W11 | - | 378.3 ± 19.2 | - | - | 1023.8 ± 72.6 | - | |
W12 | - | 128.0 ± 17.9 | - | 63.6 ± 16.6 | 211.4 ± 14.7 | 3.3 | |
W13 | 41.6 ± 11.5 | 423.8 ± 26.8 | 10.2 | 36.4 ± 16.4 | >371.7 | >10 | |
W14 | 87.1 ± 21.1 | 490.5 ± 26.8 | 5.6 | 75.4 ± 20.2 | 979.2 ± 27.8 | 13.0 | |
W15 | 69.7 ± 15.0 | 451.4 ± 32.4 | 6.5 | 65.2 ± 21.6 | 794.9 ± 33.8 | 12.2 | |
Ribavirin e | 101.2 | 836.5 | 8.3 | 114.3 | 806.6 | 7.1 |
a EC50: compound concentration required to achieve 50% protection from virus-induced cytopathogenicity; b CC50: compound concentration required to reduce cell viability by 50%; c SI (selectivity index): ratio by CC50/EC50; d Values represent the mean ± SD of three independent experiments; e Ribavirin, used as a positive control.